Attenuation of CXCR4 responses by CCL18 in acute lymphocytic leukemia B cells

Journal of Cellular Physiology

Volumn 225, Issue 3, 2010, Pages 792-800

  Catusse, J ^a   Wollner, S ^a   Leick, M ^a,b   Schrottner P ^a   Schraufstatter I ^c   Burger, M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CCL18 CHEMOKINE; CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; G PROTEIN COUPLED RECEPTOR 30; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; ANTIESTROGEN; BETA CHEMOKINE; CCL18 PROTEIN, HUMAN; CXCL12 PROTEIN, HUMAN; CXCR4 PROTEIN, HUMAN; ESTRADIOL; G PROTEIN COUPLED RECEPTOR; GPER PROTEIN, HUMAN; LIGAND; RECOMBINANT PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B LYMPHOCYTE; CALCIUM MOBILIZATION; CANCER CELL CULTURE; CELL ACTIVATION; CELL HOMING; CELL PROLIFERATION; CHEMOTAXIS; CONTROLLED STUDY; HEMATOPOIESIS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHOCYTE; PRIORITY JOURNAL; ANIMAL; APOPTOSIS; CALCIUM SIGNALING; CELL STRAIN COS1; CERCOPITHECUS; DRUG ANTAGONISM; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PRE B LYMPHOCYTE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CALCIUM SIGNALING; CELL LINE, TUMOR; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; CHEMOKINE CXCL12; CHEMOKINES, CC; CHEMOTAXIS, LEUKOCYTE; COS CELLS; ESTRADIOL; ESTROGEN ANTAGONISTS; HUMANS; LIGANDS; LYMPHOCYTE ACTIVATION; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR CELLS, B-LYMPHOID; RECEPTORS, CXCR4; RECEPTORS, G-PROTEIN-COUPLED; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 77957746670     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22284     Document Type: Article

References (44)

1. Badr G, Borhis G, Treton D, Richard Y. 2005. IFN{alpha} enhances human B-cell chemotaxis by modulating ligand-induced chemokine receptor signaling and internalization. Int Immunol 17: 459-467.
2. Bamberg CE, Mackay CR, Lee H, Zahra D, Jackson J, Lim YS, Whitfeld PL, Craig S, Corsini E, Lu B, Gerard C, Gerard NP. 2010. The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. J Biol Chem 285: 7633-7644.
3. Beider K, Abraham M, Begin M, Wald H, Weiss ID, Wald O, Pikarsky E, Abramovitch R, Zeira E, Galun E, Nagler A, Peled A. 2009. Interaction between CXCR4 and CCL20 pathways regulates tumor growth. PLoS ONE 4: e5125.
4. Bendall LJ, Baraz R, Juarez J, Shen W, Bradstock KF. 2005. Defective p38 mitogen-activated protein kinase signaling impairs chemotaxic but not proliferative responses to stromal-derived factor-1alpha in acute lymphoblastic leukemia. Cancer Res 65: 3290-3298.
5. Bleul CC, Schultze JL, Springer TA. 1998. B lymphocyte chemotaxis regulated in association with microanatomic localization, differentiation state, and B cell receptor engagement. J Exp Med 187: 753-762.
6. Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS, Parker MA, Tkachenko SE, Savchuck NP, Sklar LA, Oprea TI, Prossnitz ER. 2006. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2: 207-212.
7. Bonecchi R, Locati M, Galliera E, Vulcano M, Sironi M, Fra AM, Gobbi M, Vecchi A, Sozzani S, Haribabu B, Van Damme J, Mantovani A. 2004. Differential recognition and scavenging of native and truncated macrophage-derived chemokine (macrophage-derived chemokine/CC chemokine ligand 22) by the D6 decoy receptor. J Immunol 172: 4972-4976.
8. Bradstock KF, Makrynikola V, Bianchi A, Shen W, Hewson J, Gottlieb DJ. 2000. Effects of the chemokine stromal cell-derived factor-1 on the migration and localization of precursor-B acute lymphoblastic leukemia cells within bone marrow stromal layers. Leukemia 14: 882-888.
9. Brauweiler A, Merrell K, Gauld SB, Cambier JC. 2007. Cutting edge: Acute and chronic exposure of immature B cells to antigen leads to impaired homing and SHIP1-dependent reduction in stromal cell-derived factor-1 responsiveness. J Immunol 178: 3353-3357.
10. Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N, Kipps TJ, Burger JA. 2005. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 106: 1824-1830.
11. Busillo JM, Benovic JL. 2007. Regulation of CXCR4 signaling. Biochim Biophys Acta 1768: 952-963.
12. Catusse J, Parry CM, Dewin DR, Gompels UA. 2007. Inhibition of HIV-1 infection by viral chemokine U83A via high-affinity CCR5 interactions that block human chemokine-induced leukocyte chemotaxis and receptor internalization. Blood 109: 3633-3639.
13. Comerford I, Litchfield W, Harata-Lee Y, Nibbs RJ, McColl SR. 2007. Regulation of chemotactic networks by 'atypical' receptors. Bioessays 29: 237-247.
14. Dubeykovskaya Z, Dubeykovskiy A, Solal-Cohen J, Wang TC. 2009. Secreted trefoil factor 2 activates the CXCR4 receptor in epithelial and lymphocytic cancer cell lines. J Biol Chem 284: 3650-3662.
15. Filardo EJ, Quinn JA, Bland KI, Frackelton AR, Jr. 2000. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 14: 1649-1660.
16. Filardo EJ, Thomas P. 2005. GPR30: A seven-transmembrane-spanning estrogen receptor that triggers EGF release. Trends Endocrinol Metab 16: 362-367.
17. Fitzsimons CP, Gompels UA, Verzijl D, Vischer HF, Mattick C, Leurs R, Smit MJ. 2006. Chemokine-directed trafficking of receptor stimulus to different g proteins: Selective inducible and constitutive signaling by human herpesvirus 6-encoded chemokine receptor U51. Mol Pharmacol 69: 888-898.
18. Gamba L, Cubedo N, Ghysen A, Lutfalla G, Dambly-Chaudiere C. 2010. Estrogen receptor ESR1 controls cell migration by repressing chemokine receptor CXCR4 in the zebrafish posterior lateral line system. Proc Natl Acad Sci USA 107: 6358-6363.
19. Garzon R, Soriano SF, Rodriguez-Frade JM, Gomez L, Martin de Ana A, Sanchez-Gomez M, Martinez AC, Mellado M. 2004. CXCR4-mediated suppressor of cytokine signaling up-regulation inactivates growth hormone function. J Biol Chem 279: 44460-44466.
20. Geay JF, Buet D, Zhang Y, Foudi A, Jarrier P, Berthebaud M, Turhan AG, Vainchenker W, Louache F. 2005. p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression. Cancer Res 65: 2676-2683.
21. Hartmann TN, Leick M, Ewers S, Diefenbacher A, Schraufstatter I, Honczarenko M, Burger M. 2008. Human B cells express the orphan chemokine receptor CRAM-A/B in a maturation-stage-dependent and CCL5-modulated manner. Immunology 125: 252-262.
22. Honczarenko M, Douglas RS, Mathias C, Lee B, Ratajczak MZ, Silberstein LE. 1999. SDF-1 responsiveness does not correlate with CXCR4 expression levels of developing human bone marrow B cells. Blood 94: 2990-2998.
23. Juarez J, Bradstock KF, Gottlieb DJ, Bendall LJ. 2003. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia 17: 1294-1300.
24. Kang L, Zhang X, Xie Y, Tu Y, Wang D, Liu Z, Wang ZY. 2010. Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling. Mol Endocrinol 24: 709-721.
25. Kubarek L, Jagodzinski PP. 2007. Epigenetic up-regulation of CXCR4 and CXCL12 expression by 17 beta-estradiol and tamoxifen is associated with formation of DNA methyltransferase 3B4 splice variant in Ishikawa endometrial adenocarcinoma cells. FEBS Lett 581: 1441-1448.
26. Kvingedal AM, Smeland EB. 1997. A novel putative G-protein-coupled receptor expressed in lung, heart and lymphoid tissue. FEBS Lett 407: 59-62.
27. Langer G, Bader B, Meoli L, Isensee J, Delbeck M, Noppinger PR, Otto C. 2010. A critical review of fundamental controversies in the field of GPR30 research. Steroids 75: 603-610.
28. Lataillade JJ, Clay D, Dupuy C, Rigal S, Jasmin C, Bourin P, Le Bousse-Kerdiles MC. 2000. Chemokine SDF-1 enhances circulating CD34(+) cell proliferation in synergy with cytokines: Possible role in progenitor survival. Blood 95: 756-768.
29. Lee Y, Gotoh A, Kwon HJ, You M, Kohli L, Mantel C, Cooper S, Hangoc G, Miyazawa K, Ohyashiki K, Broxmeyer HE. 2002. Enhancement of intracellular signaling associated with hematopoietic progenitor cell survival in response to SDF-1/CXCL12 in synergy with other cytokines. Blood 99: 4307-4317.
30. Leick M, Catusse J, Follo M, Nibbs RJ, Hartmann TN, Veelken H, Burger M. 2010. CCL19 is a specific ligand of the constitutively recycling atypical human chemokine receptor CRAM-B. Immunology 129: 536-546.
31. Levin ER. 2009. G protein-coupled receptor 30: Estrogen receptor or collaborator? Endocrinology 150: 1563-1565.
32. Mowafi F, Cagigi A, Matskova L, Bjork O, Chiodi F, Nilsson A. 2008. Chemokine CXCL12 enhances proliferation in pre-B-ALL via STAT5 activation. Pediatr Blood Cancer 50: 812-817.
33. Nibbs RJ, Salcedo TW, Campbell JD, Yao XT, Li Y, Nardelli B, Olsen HS, Morris TS, Proudfoot AE, Patel VP, Graham GJ. 2000. C-C chemokine receptor 3 antagonism by the beta-chemokine macrophage inflammatory protein 4, a property strongly enhanced by an amino-terminal alanine-methionine swap. J Immunol 164: 1488-1497.
34. Owman C, Blay P, Nilsson C, Lolait SJ. 1996. Cloning of human cDNA encoding a novel heptahelix receptor expressed in Burkitt's lymphoma and widely distributed in brain and peripheral tissues. Biochem Biophys Res Commun 228: 285-292.
35. Palmesino E, Moepps B, Gierschik P, Thelen M. 2006. Differences in CXCR4-mediated signaling in B cells. Immunobiology 211: 377-389.
36. Patrick CW, Jr., Smith TW, McIntire LV, Juneja HS. 1996. Cellular interactions among marrow stromal and normal/neoplastic pre-B- and B-lymphoblastic cells. Leuk Lymphoma 22: 205-219.
37. Percherancier Y, Berchiche YA, Slight I, Volkmer-Engert R, Tamamura H, Fujii N, Bouvier M, Heveker N. 2005. Bioluminescence resonance energy transfer reveals ligand-induced conformational changes in CXCR4 homo- and heterodimers. J Biol Chem 280: 9895-9903.
38. Schutyser E, Richmond A, Van Damme J. 2005. Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. J Leukoc Biol 78: 14-26.
39. Schutyser E, Struyf S, Proost P, Opdenakker G, Laureys G, Verhasselt B, Peperstraete L, Van de Putte I, Saccani A, Allavena P, Mantovani A, Van Damme J. 2002. Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J Biol Chem 277: 24584-24593.
40. Sipkins DA, Wei X, Wu JW, Runnels JM, Cote D, Means TK, Luster AD, Scadden DT, Lin CP. 2005. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature 435: 969-973.
41. Struyf S, Schutyser E, Gouwy M, Gijsbers K, Proost P, Benoit Y, Opdenakker G, Van Damme J, Laureys G. 2003. PARC/CCL18 is a plasma CC chemokine with increased levels in childhood acute lymphoblastic leukemia. Am J Pathol 163: 2065-2075.
42. Wigler M, DeFeo D, Weinstein IB. 1978. Induction of plasminogen activator in cultured cells by macrocyclic plant diterpene esters and other agents related to tumor promotion. Cancer Res 38: 1434-1437.
43. Wimmer A, Khaldoyanidi SK, Judex M, Serobyan N, Discipio RG, Schraufstatter IU. 2006. CCL18/PARC stimulates hematopoiesis in long-term bone marrow cultures indirectly through its effect on monocytes. Blood 108: 3722-3729.
44. Wu X, Lee VC, Chevalier E, Hwang ST. 2009. Chemokine receptors as targets for cancer therapy. Curr Pharm Des 15: 742-757.